Zydus Cadila Seeks DCGI Nod To Undertake Clinical Trials for Monoclonal Antibodies Cocktail That Can Neutralise COVID-19 Infection
Zydus Cadila has sought the approval of the Drugs Controller General of India (DCGI) to undertake clinical trials for monoclonal antibodies cocktail that can neutralise COVID-19 infection.
Pharmaceutical company Zydus Cadila on Thursday sought the approval of the Drugs Controller General of India (DCGI) to undertake clinical trials for monoclonal antibodies cocktail that can neutralise COVID-19 infection.Â
Zydus seeks DCGI approval to undertake clinical trials for monoclonal antibodies cocktail that can neutralise #COVID infection: Zydus Cadila
— ANI (@ANI) May 27, 2021
(SocialLY brings you all the latest breaking news, fact checks and information from social media world, including Twitter (X), Instagram and Youtube. The above post contains publicly available embedded media, directly from the user's social media account and the views appearing in the social media post do not reflect the opinions of LatestLY.)
(The above story first appeared on LatestLY on May 27, 2021 10:29 AM IST. For more news and updates on politics, world, sports, entertainment and lifestyle, log on to our website latestly.com).
